• Logo
  • SBMUJournals

Prevalence and Prognostic Role of PIK3CA E545K Mutation in Iranian Colorectal Cancer Patients

Reza Ranjbar, Somayeh Mohammadpour, Amir Torshizi Esfahani, Sina Namazian, Mohammad Yaghob-Taleghani, Kaveh Baghaei, Seyed Abdolreza Mortazavi Tabatabaei, Leila Pasharavesh, Ehsan Nazemalhosseini Mojarad




Aim: This study aimed to evaluate the distribution of PIK3CA E545K mutation in Iranian CRC patients and explored its roles in disease prognosis.

Background: Deregulation of the phosphoinositide 3-kinase (PI3K) pathway contributes to the progression of tumors. The p110a (PIK3CA), a catalytic subunit of PIK3, is mutated in many types of cancers. Exon 9 (E545K) is the most frequently mutated hotspot in PIK3CA in colorectal cancer (CRC). However, the prognostic role of PIK3CA E545K mutation needs to be elucidated.

Methods: Tumors from 187 CRC patients were retrospectively collected from the Taleghani and Shohada Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, between 2010 and 2017. PIK3CA E545K status was detected in Formalin-fixed paraffin-embedded (FFPE) tissues using PCR-RFLP methods, and validated by pyrosequencing. Correlations between PIK3CA E545K mutation clinicopathological features were analyzed.

Results: The frequency of PIK3CA E545K gene mutations in CRC patients was 10.7%. Significant correlations were observed in PIK3CA E545K mutation with tumor differentiation and TNM stage (p < 0.042 and p = 0.033, respectively). Kaplan–Meier analysis showed a worse prognosis in overall survival (OS) in patients with PIK3CA E545K mutation (p < 0.001). Multivariate analysis indicated that PIK3CA E545K mutation was a detrimental factor for OS (HR = 6.497, 95% CI: 2.859-14.768, p < 0.021).

Conclusion: A high frequency of PIK3CA E545K mutation was detected in Iranian CRC patients. The results of the present study suggested that PIK3CA E545K mutation may be associated with poor prognosis. These findings require further confirmation via prospective studies with larger samples.

Keywords: PIK3CA, Mutation, Prognosis, Colorectal cancer.

(Please cite as: Ranjbar R, Mohammadpour S, Torshizi Esfahani A, Namazian S, Yaghob-Taleghani M, Baghaei K, et al. Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients. Gastroenterol Hepatol Bed Bench 2019;12(Suppl.1):22-29).


PIK3CA, Mutation, Prognosis, Colorectal cancer.


Herman PK, Stack JH, DeModena JA, Emr SD. A novel protein kinase homolog essential for protein sorting to the yeast lysosome-like vacuole. Cell 1991;64:425-37.

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Ann Rev Cell Dev Biol 2001;17:615-75.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild‐type metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: a systematic review with meta‐analysis. Int J Cancer 2013;133:1914-25.

Stintzing S, Lenz HJ. A Small Cog in a Big Wheel: PIK3CA Mutations in Colorectal Cancer. J Natl Cancer Inst 2013;105:1775-6.

Brown KK, Toker A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep 2015;7:13.

Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33:2949.

Papadatos-Pastos D, Rabbie R, Ross P, Sarker D. The role of the PI3K pathway in colorectal cancerCrit Rev Oncol Hematol 2015;94:18-30.

Koboldt D, Fulton R, McLellan M, McLellan M, Schmidt H, Kalicki-Veizer J, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.

Stec R, Semeniuk-Wojtaś A, Charkiewicz R, Bodnar L, Korniluk J, Smoter M, et al. Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. Oncol lett 2015;10:1423-9.

Baker CL, Vaughn CP, Samowitz WS. A PIK3CA pyrosequencing-based assay that excludes pseudogene interference. J Mol Diagn 2012;14:56-60.

Mik M, Berut M, Dziki L, Trzcinski R, Dziki A. Right-and left-sided colon cancer–clinical and pathological differences of the disease entity in one organ. Arch Med Sci 2017;13:157.

Dogruluk T, Tsang YH, Espitia M, Chen F, Chen T, Chong Z, et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res 2015;75:5341-54.

Cathomas G. PIK3CA in colorectal cancer. Front Oncol 2014;4:35.

Mei ZB, Duan CY, Li CB, Cui L, Ogino S. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2016;27:1836-48.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Sci 2004;304:554.

Thirumal Kumar D, George Priya Doss C. Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach. J Biomol Struct Dyn 2017;35:2745-57.

Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers PloS One 2011;6:e22769.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013;13:49.

Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009;15:3184-8.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. lancet Oncol 2010;11:753-62.

Samuels Y, Diaz Jr LA, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.

Leontiadou H, Galdadas I, Athanasiou C, Cournia Z. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Sci Rep 2018;8:15544.

Wang Q, Shi YL, Zhou K, Wang LL, Yan ZX, Liu YL, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis 2018;9:739.

Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.

Nazemalhosseini-Mojarad E, Farahani RK, Mehrizi M, Baghaei K, Taleghani MY, Golmohammadi M, et al. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. J Gastrointest Cancer 2019:1-0.

Larki P, Gharib E, Taleghani MY, Khorshidi F, Nazemalhosseini-Mojarad E, Aghdaei HA. Coexistence of KRAS and BRAF mutations in colorectal cancer: a case report supporting the concept of tumoral heterogeneity. Cell J 2017;19:113.

Torshizi-Esfahani A, Seyedna SY, Nazemalhosseini-Mojarad E, Majd A, Asadzadeh-Aghdaei H. MSI‐L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients. J Cell Physiol 2019;234:13128-36.

DOI: https://doi.org/10.22037/ghfbb.v12i0.1829